Ruxolitinib as a Front-Line Therapy for Children With Secondary Hemophagocytic Lymphohistiocytosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Haematologica
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Pilot Study of Ruxolitinib as a Front-Line Therapy for 12 Children With Secondary Hemophagocytic Lymphohistiocytosis
Haematologica 2020 Jul 30;[EPub Ahead of Print], Q Zhang, A Wei, HH Ma, L Zhang, HY Lian, D Wang, YZ Zhao, L Cui, WJ Li, Y Yang, TY Wang, ZG Li, R ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.